Cited by 40Neurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology ResearchNicotinic Acetylcholine Receptors Study

Neural Basis of Benzodiazepine Reward: Requirement for α2 Containing GABAA Receptors in the Nucleus Accumbens

Open access
Engin, Elif, Bakhurin, Konstantin I, Smith, Kiersten S, Hines, Rochelle M, Reynolds, Lauren M, Tang, Wannan, Sprengel, Rolf, Moss, Stephen J +1 more·2014·Neuropsychopharmacology

Abstract

Despite long-standing concerns regarding the abuse liability of benzodiazepines, the mechanisms underlying properties of benzodiazepines that may be relevant to abuse are still poorly understood. Earlier studies showed that compounds selective for α1-containing GABAA receptors (α1GABAARs) are abused by humans and self-administered by animals, and that these receptors may underlie a preference for benzodiazepines as well as neuroplastic changes observed in the ventral tegmental area following benzodiazepine administration. There is some evidence, however, that even L-838, 417, a compound with antagonistic properties at α1GABAARs and agonistic properties at the other three benzodiazepine-sensitive GABAA receptor subtypes, is self-administered, and that the α2GABAARs may have a role in benzodiazepine-induced reward enhancement. Using a two-bottle choice drinking paradigm to evaluate midazolam preference and an intracranial self-stimulation (ICSS) paradigm to evaluate the impact of midazolam on reward enhancement, we demonstrated that mice carrying a histidine-to-arginine point mutation in the α2 subunit which renders it insensitive to benzodiazepines (α2(H101R) mice) did not prefer midazolam and did not show midazolam-induced reward enhancement in ICSS, in contrast to wild-type controls, suggesting that α2GABAARs are necessary for the reward enhancing effects and preference for oral benzodiazepines. Through a viral-mediated knockdown of α2GABAARs in the nucleus accumbens (NAc), we demonstrated that α2 in the NAc is necessary for the preference for midazolam. Findings imply that α2GABAARs in the NAc are involved in at least some reward-related properties of benzodiazepines, which might partially underlie repeated drug-taking behavior.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2014.41

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • α2GABAARs in the NAc are necessary to maintain midazolam preference in a two-bottle choice drinking test.

    “Moreover, positive modulation of α2GABAARs is required for the reward-enhancing effects of benzodiazepines [106], and α2GABAARs in the NAc are necessary to maintain midazolam preference in a two-bottle choice drinking test [107].”

    From An emerging circuit pharmacology of GABAA receptors (2018) · cites this paper as [107]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Engin, E., Bakhurin, K. I., Smith, K. S., Hines, R. M., Reynolds, L. M., Tang, W., Sprengel, R., Moss, S. J., & Rudolph, U.
Affiliations
  • Harvard University (US)
  • Tufts University (US)
  • Max Planck Institute for Medical Research (DE)
Corresponding author
Engin, Elif
Venue
Neuropsychopharmacology
Published
2014-02-19
Volume
39
Issue
8
Pages
1805-1815
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W1993753770
Cited by
40
References
64
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 8 · 2015: 6 · 2014: 5
FWCI
3.35
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Max Planck Digital Library (submittedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion)
Funders
  • Canadian Institutes of Health Research
  • National Institute of Mental Health (R01MH080006, MH097446, R01MH097446)
  • National Institute on Drug Abuse (R03DA027051)
  • National Institute of Neurological Disorders and Stroke (R01NS051195, NS 056359, NS 051195, R01NS056359, NS081735)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
benzodiazepines, drug reward, nucleus accumbens, midazolam, drug preference, intracranial self-stimulation, abuse liability, GABAA receptor subtypes
MeSH terms
Animals, Choice Behavior, Male, Mice, Transgenic, Midazolam, Nucleus Accumbens, Receptors, GABA-A, Reward, GABA Modulators, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review